Microglia, which are pathological effectors and amplifiers in the central nervous system, undergo various forms of activation. A well-studied microglial-induced pathological paradigm, spinal microglial activation following peripheral nerve injury (PNI), is a key event for the development of neuropathic pain but the transcription factors contributing to microglial activation are less understood. Herein, we demonstrate that MafB, a dominant transcriptional regulator of mature microglia, is involved in the pathology of a mouse model of neuropathic pain. PNI caused a rapid and marked increase of MafB expression selectively in spinal microglia but not in neurons. We also found that the microRNA mir-152 in the spinal cord which targets MafB expression decreased after PNI, and intrathecal administration of mir-152 mimic suppressed the development of neuropathic pain. Reduced MafB expression using heterozygous Mafb deficient mice and by intrathecal administration of siRNA alleviated the development of PNI-induced mechanical hypersensitivity. Furthermore, we found that intrathecal transfer of Mafb deficient microglia did not induce mechanical hypersensitivity and that conditional Mafb knockout mice did not develop neuropathic pain after PNI. We propose that MafB is a key mediator of the PNIinduced phenotypic alteration of spinal microglia and neuropathic pain development.
the microglial cell cycle and cell propagation in the perinatal brain (Zusso et al., 2012) , Sal-like protein 1 was recently identified as the predominant regulator of adult microglial genes (Buttgereit et al., 2016; Matcovitch-Natan et al., 2016) , and interferon regulatory factor 8 (IRF8) is essential for the development of neonatal microglia (Kierdorf et al., 2013) . Of the above factors, IRF8 is induced in mature microglia to exert proinflammatory roles and in spinal cord microglia in neuropathic pain models (Akagi et al., 2014; Masuda et al., 2012) ; however, IRF8 does not fully explain the microglial phenotypic change in neuropathic pain. From the hypothesis that transcription factors regulating microglial development share some mechanisms with the phenotypic changes in a pathological event during adulthood, we focused on a member of the large Maf family of transcription factors, MafB, which has basic leucine-zipper DNA-binding motifs and Nterminal transactivation domains (Eychene, Rocques, & Pouponnot, 2008; Nishizawa, Kataoka, Goto, Fujiwara, & Kawai, 1989) . It is recognized as a key regulator of tissue-specific gene expression and cell differentiation in, for example, macrophages, podocytes, and pancreatic α and β cells (Eychene et al., 2008; Hang & Stein, 2011; Kataoka, 2007) . In the hematopoietic cell lineage, MafB commits monocytes to differentiate into macrophages rather than dendritic cells, suggesting MafB has the potential to shape the macrophage phenotype (Bakri et al., 2005; Friedman, 2007; Kelly, Englmeier, Lafon, Sieweke, & Graf, 2000) . Recent studies indicate that microglia and tissue-resident macrophages share primitive myeloid progenitor cells as an origin (Ginhoux et al., 2010; Ransohoff & Cardona, 2010; Saijo, Collier, Li, Katzenellenbogen, & Glass, 2011) . MafB is expressed predominantly in adult microglia and regulates gene sets related to immune activation (Matcovitch-Natan et al., 2016; Silvin & Ginhoux, 2018) . Thus, we assessed MafB expression and function in spinal microglia and its involvement in pathogenesis using a well-established mouse model of neuropathic pain that demonstrated upregulation of MafB in spinal microglia, and crucial role of MafB in microglia for development of PNI-induced mechanical hypersensitivity.
| MATERIALS AND METHODS

| Animals
Male WT C57BL/6J mice were purchased from CLEA Japan, Inc. Male plt mice (Mori et al., 2001; were kindly provided by Prof. Terutaka Kakiuchi (Department of Immunology, Toho University School of Medicine). Mafb +/GFP mice (Moriguchi et al., 2006) were kindly provided by Prof. Satoru Takahashi (Department of Anatomy and Embryology, University of Tsukuba). Since Mafb deficient mice (Mafb GFP/GFP ) are lethal in neonatal stage (Moriguchi et al., 2006) , the mice were maintained heterozygously. Mafb-flox mice (Yu et al., 2013) were kindly provided by Prof. Lisa Goodrich (Department of Neurobiology, Harvard Medical School).
Cx3cr1-CreERT2 mice were purchased from Jackson Laboratory. For induction of Cre recombinase and generation of microglia specific knockout, 5-week-old Cx3cr1-CreERT2 mice were injected s.c. with 2 mg of tamoxifen (Sigma, St. Louis, MO) dissolved in 100 μl corn oil (Wako, Osaka, Japan), twice with a 48 hr interval (Wieghofer, Knobeloch, & Prinz, 2015) . Mice were housed at a constant temperature of 22 AE 1 C with a 12 hr light-dark cycle (light on 8:00 to 20:00), and were fed food and water ad libitum. All animal experiments were conducted in accordance with the guidelines of Kyushu University.
| Neuropathic pain model
For the neuropathic pain model, we used the spinal PNI model (Kim & Chung, 1992) with some modifications (Rigaud et al., 2008; Tsuda, Kuboyama, et al., 2009) . In brief, while mice were under 2% isoflurane anesthesia, a small left-side incision was made at L3-S1. Paraspinal muscle and fat were separated from the L5 traverse process, and part of this traverse process was removed to expose the parallel-lying L3
and L4 spinal nerves. The L4 nerve was isolated and amputated. The wound and the surrounding skin were sutured with 5-0 silk and a surgical stapler. We treated the result from contralateral side of injury as an experimental control instead of using sham-treated animals.
| Real-time quantitative RT-PCR analysis
Total RNA from L4 spinal cords of mice were extracted using Trisure (Bioline, Humber Road, London) according to the manufacturer's protocol. The amount of total RNA was quantified by measuring optical density at 260 nm (OD 260 ) using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE). Total RNA from sorted cells was extracted and purified with the NucleoSpin RNA XS kit (Takara, Otsu, Japan). Prime Script reverse transcriptase (Takara) was used for reverse transcription with random 6-mer primers. Quantitative PCR for the obtained cDNA was performed with Premix Ex Taq (Takara) using a 7500 real-time PCR system (Applied Biosystems, Foster City, CA) according to the protocol of the manufacturer, and the data were analyzed with 7500 System SDS Software 1.3.1 (Applied Biosystems) using the standard curve method. All values were normalized to 18S ribosomal RNA expression except for values from sorted cells that were normalized to the total cell number in the sample (3,000 cells).
Sequences of the forward primer, reverse primer, and TaqMan probe are listed in 
| Immunohistochemistry
Mice deeply anesthetized by intraperitoneal injection of pentobarbital were perfused transcardially with ice-cold phosphate buffered saline (PBS) followed by 4% (w/v) paraformaldehyde/PBS. The L4 segments of the spinal cord were removed, postfixed in the same fixative for 3 hr at 4 C, and placed in 30% (w/v) sucrose solution for 24 hr at 4 C.
A subset of transverse spinal cord sections (30 μm) was cut from the center region of L4 segments and incubated in blocking solution (3% v/v normal goat serum) for 2 hr at room temperature. The sections were then incubated for 48 hr at 4 C with the primary antibodies for
MafB (rabbit polyclonal, 1:3,000, Bethyl, Montgomery, TX, Supporting
Information Figure S1 ), CD11b (rat monoclonal 5C6 
| Intrathecal catheter placement
For intrathecal injection in mice, we used intrathecal catheter placement (Tsuda, Masuda, et al., 2009; Yaksh, Jessell, Gamse, Mudge, & Leeman, 1980) with some modifications. While mice were under 2% isoflurane anesthesia, a 32-gauge intrathecal catheter (ReCathCo, Allison Park, PA) was inserted through the atlanto-occipital membrane into the lumbar enlargement (close to the L4 segment) and externalized through the skin. The catheter placement was verified by the observation of hind limb paralysis induced by intrathecal administration of lidocaine (2%, 5 μl). Mice that failed to exhibit paralysis were excluded from the experiments.
| Behavioral tests
To assess mechanical hypersensitivity, mice were placed individually in an opaque plastic cylinder, which was placed on wire mesh, and habituated for 1 hr to allow acclimation to the measuring environment. After that, calibrated von Frey filaments (0.02-2.0 g, Stoelting)
were applied to the plantar surface of the hindpaw from below the mesh floor, and the 50% paw withdrawal threshold (PWT) was determined using the up-down method (Chaplan, Bach, Pogrel, Chung, & Yaksh, 1994) . The PWT was measured before and after L4 spinal PNI in siRNA-treated mice. To assess inflammatory pain, CFA (0.01 mg per 20 μl, Sigma) was injected subcutaneously in the plantar surface of left hindpaw under transient restraint, and the 50% PWT was determined using the up-down method (Chaplan et al., 1994) .
For the hot-plate test, mice were placed on a metal surface maintained at 45, 49, or 52 C within a 25-cm-high Plexiglass box (25 × 25 cm). The latency to either lick the hindpaw or jump was recorded as a nocifensive endpoint (Cao et al., 1998) . Noxious heatevoked tail-flick responses were measured following the application of radiant heat (Ugo Basile, Italy) to the tail. The intensity of the heat stimulus was adjusted to 50 V, and the latency of the tail withdrawal response (in s) was measured .
In the tests of formalin-induced pain, mice were housed in individual boxes and allowed to habituate to the testing environment for 15 min. Then, mice were injected intraplantarly with formalin (5%, 10 μl, The duration of the licking and biting of the injected hindpaw was recorded at 5 min intervals for 60 min after the injection (Tsuda et al., 2007) . Durations between 0-10 min and 30-60 min after injection were separated as the first and second phases of formalininduced pain.
| Cell culture
Mouse primary cultured microglia from Mafb GFP/GFP mice were prepared in accordance with a method described previously (Biber et al., 2011; Nakajima et al., 1992) with some modifications. Briefly, pairs of Mafb +/GFP mice were mated overnight, and pregnant mice were used to obtain E18-19 embryos. A mixed glial culture was prepared for individual embryos whose genotypes were determined for each culture. Embryos were not divided by sex. The cultures were maintained for 9-15 days in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS). Immediately before experiments, microglia were collected by gentle shaking, as the cells floated over the mixed glial culture, and were transferred to the appropriate culture dish for subsequent experiments.
| Microglia transfer
Primary microglia were prepared as described above. Cells were plated in 60 mm UpCell ® culture dishes (CellSeed Inc, Tokyo, Japan), which have low cell attachment property at room temperature. After a 1 hr incubation at 37 C, ATP (50 μM) or PBS was added and cells were incubated for 1 hr. The medium was replaced by HBSS(−) and the cells detached at room temperature. Microglia were collected by pipetting, centrifuged, and resuspended to adjust cell concentration to 2 × 10 3 cells/μl in HBSS(−), then 10 4 cells were injected through the implanted catheter.
| Treatment with siRNA and microRNA mimic
To transfect siRNA, Stealth RNAi with the Lipofectamine™ RNAiMAX transfection system (Invitrogen, Japan) was used. Stealth RNA targeting Mafb mRNA and control Stealth RNA were designed by and purchased from Invitrogen, and the transfection procedure was performed generally according to the manufacturer's guidelines. The sequences are listed in Table 2 . For in vivo siRNA treatment, we treated mice with Stealth RNA (20 pmol, 4 μl, 1:1 mixture with Lipofectamine™ RNAiMAX) through the implanted intrathecal catheter twice per day for 3 days before spinal PNI.
For microRNA mimic and negative control, we chose hsa-miR-152 mirVana miRNA mimic (Assay ID: MC12269) and mirVanaTM miRNA mimic Negative Control #1(Ambion). Reagents (25 pmol) were premixed with Lipofectamine™ RNAiMAX (Invitrogen) and intrathecally administered through the implanted catheter at the volume 5 μl.
| Statistical analysis
All data are presented as mean AE SEM. 3 | RESULTS
| PNI upregulates MafB expression in spinal microglia
To investigate MafB expression in a PNI model of neuropathic pain (4th lumbar spinal nerve transection), we used Mafb GFP/+ mice (Moriguchi et al., 2006) that have a Mafb allele replaced with cDNA encoding GFP and that express GFP in a manner that depends on To see the intrinsic MafB expression, we used wild-type C57BL6J mice and found that the levels of Mafb mRNA in the L4 spinal cord after PNI were significantly increased in the ipsilateral side from day 3 to at least day 21 (Figure 1f ). We next performed Figure 1i ).
These observations demonstrate that the PNI-induced MafB upregulation selectively occurs in microglia and not in neurons in the spinal dorsal horn.
| Microglial MafB expression is elevated early after PNI
We considered that MafB could have a role in induction of activated microglia in response to PNI. We therefore examined its expression at earlier time points following PNI; a PNI-induced increase in MafB-IF in spinal microglia with activated morphology was already observed as early as day 1 (Figure 2a) . In histogram analysis of MafB-IF intensity per individual microglial cell, the distribution of MafB-IF intensities was skewed to the right at day 1 and gradually reduced its expression level by day 7 while MafB-positive cell number increased (Figure 2b ).
The number of MafB-positive microglia were significantly increased from day 1 and maintained after day 3 to day 7 after PNI ( Figure 2c ).
The mean intensity of MafB-IF per microglial cell was 2.8-fold higher on average in the ipsilateral compared with the contralateral dorsal horn, and its increased expression gradually decreased after day 1 (Figure 2d) . Interestingly, in microglia isolated from the spinal cord by fluorescence-activated cell sorting (FACS), the levels of Mafb mRNA from an equal number of CD11b + microglial cells were not changed by PNI (Figure 2e ). In contrast, Aif1 (Iba1) mRNA was increased in the same samples at day 3 post-PNI (Figure 2f ). These findings suggest that mRNA upregulation observed from day 3 post-PNI (Figure 1f ) was a result from the increasing population of microglia by its proliferation in the spinal cord after PNI (Supporting information Figure S2 
| Microglial MafB contributes to mechanical hypersensitivity
To investigate the role of MafB in neuropathic pain, we again utilized Their 5-week-old offspring were treated with tamoxifen (Figure 4d ), as controlled Mafb fl/fl mice, to obtain microglia specific MafB knockout mice (Supporting Information Figure S4 ) and Cx3cr1
;Mafb fl/fl mice with corn oil vehicle as same genotype control. We subjected these groups of mice to PNI, and found that microglia specific MafB knockout resulted in a significant reduction of allodynic behavior (Figure 4e ). These results strongly suggest that microglial MafB contributes to neuropathic pain
development.
Finally, we tested the effect of MafB-targeted short interfering RNA (siMafB) administered intrathecally to knock down spinal MafB to achieve more shorter duration of MafB knock down before PNI. In mice treated intrathecally with siMafB twice per day for 3 days before PNI (Figure 5a ), the PNI-induced increase in MafB-IF intensity per spinal microglial cell was reduced in siMafB-treated groups (49% reduction, Supporting Information Figure S5a,b) . The number of MafBpositive microglia was not changed (Supporting Information Figure S5c ).
In von Frey testing, the PNI-induced mechanical hypersensitivity was significantly alleviated in siMafB-treated mice (Figure 5b ). The threshold was unchanged for the hindpaw contralateral to the PNI and no abnormal motor dysfunction was observed. At day 7 in the spinal cord, we found that P2rx4 and P2rx7 mRNA upregulation was significantly suppressed in the siMafB-treated mice (Figure 5c ). Iba1 (Aif1), Irf8, Irf5, and Mice received PNI were subjected to treatment of mir-152 mimic or negative control, and paw withdrawal thresholds were measured for 7 days (n = 8 each, day 1; *p < .05; t = 2.154, day 3; ***p < .001; t = 3.934, day 5; ***p < .001; t = 5.660, day 7; **p < .01; t = 3.310, ipsilateral side of miR-negative control vs. miR-152 mimic, two-way repeated measures ANOVA [p < .001, F = 7.004] post hoc Bonferroni t test). (Figure 2e ). Therefore, we considered that PNI-induced
Mafb mRNA increase in spinal cord may be due to the increase in the number of MafB + microglia since microglial proliferation is usually observed after day 2 after PNI (Echeverry, Shi, & Zhang, 2008; Suter, Berta, Gao, Decosterd, & Ji, 2009; Tsuda et al., 2011; Supporting Informa- tion Figure S2 ), and that the data from isolated microglia indicate little alteration in Mafb mRNA levels in individual spinal microglial cells. Then we thought posttranscriptional regulation of MafB. A possible explanation
for MafB-IF upregulation may be a microRNA-mediated translational regulation (Ponomarev, Veremeyko, & Weiner, 2013) . We revealed that transient reduction of mir-152 in the spinal cord after PNI and supplementation of this microRNA clearly suppressed the development of neuropathic pain. MicroRNA usually target set of genes, thus the behavioral effect observed here may not be caused by merely a MafB downregulation; however, the fact that mir-152 directly regulates MafB expression has been proved by 3 0 UTR reporter assay (Li et al., 2017) .
Thus, it was suggested that the effect of mir-152 supplementation was at least in part due to reactivation of translational repression activity of mir-152 on MafB. Other factors may also be involved in the MafB expression, indeed we found that intrathecal CCL21 increased MafB expression in spinal microglia (Supporting Information Figure S7 ). This chemokine is produced in damaged primary afferent neurons immediately after PNI and transported to their central terminals in the dorsal horn, where it contributes to pain hypersensitivity (Biber et al., 2011) , implying a direct induction of MafB in microglia by the injured-neuron-derived factor.
However, reduced expression of MafB in CCL21 deficient mice (plt) after PNI was partial, and CCL21 administration did not suppress mir-152 expression in the spinal cord thus there may be several parallel pathways regulating MafB expression. Another possibility may involve an increase in stability of the MafB protein. MafB is subjected to negative regulation through the ubiquitin-proteasome pathway (Tanahashi, Kito, Ito, & Yoshioka, 2010) or ncRNA mediated-translational regulation (Zhang, Zhang, & Yu, 2012) , and also a conformational change in the transcriptional complex which exposes epitopes in the MafB protein can also be involved in the MafB-IF upregulation.
Our behavioral assays in chronic pain models revealed the crucial role of MafB in neuropathic mechanical hypersensitivity. As the data from in lamina III and ventral spinal cord that is consistent with a recent report (Bikoff et al., 2016; Del Barrio et al., 2013) . Thus, a contribution of neuronal MafB to sensory processing was suspected as a cause of pain reduction. either Irf8 and Irf5, transcription factors whose expression is upregulated selectively in spinal microglia after PNI , but in additional assessments we found that siMafB given in the maintenance phase had no effect on the PNI-induced hypersensitivity (Supporting Information Figure S6a ) and MafB conditional knockout by tamoxifen administration from 7 days after PNI did not affect established mechanical allodynia (Supporting Information Figure S6b ). As our data demonstrated, modulation of MafB expression at early time point after PNI were effective to suppress the development of neuropathic pain, but MafB seems no longer have regulatory role after neuropathic pain established.
MafB in spinal microglia may have a role of triggering P2X4
receptor-positive microglial activation that has a crucial role in the development of neuropathic pain (Beggs, Trang, & Salter, 2012) . Our data from qPCR analysis of siMafB-treated mice indicates MafB is involved in P2X4 and P2X7 receptor expression. It has been known that there is sexual dimorphism in microglial P2X4 receptor-evoked pain hypersensitivity (Sorge et al., 2015) . Since all our experiment done with male mice and our data suggested an involvement of P2X4
receptor as a target of MafB, MafB contribution to neuropathic pain in female needs to be carefully analyzed in future study.
In summary, our present data provide evidence that PNI increases
MafB expression in spinal microglia in the early phase of neuropathic pain, at least in part through mir-152 mediated regulation, and that
MafB is a necessary factor to trigger the microglia-mediated development of neuropathic pain.
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*** *** *** *** MafB downregulation by siRNA suppressed the development of neuropathic pain. (a) Mafb-specific siRNA (siMafB) or control siRNA (siCont) was intrathecally injected (20 pmol/mouse) twice per day for 3 days before PNI. (b) Paw withdrawal thresholds against von Frey filaments were measured in contralateral and ipsilateral hindpaw (n = 11 for siCont, n = 12 for siMafB; day 1; ***p < .001; t = 3.636, day 3; ***p < .001; t = 3.414, day 5; ***p < .001; t = 4.659, day 7; ***p < .001; t = 3.993, two-way repeated measures ANOVA [p = .002; F = 4.521] post hoc Bonferroni t test), 50% withdrawal thresholds are shown. (c) Gene expression in the spinal cord 7 days after PNI was assessed by qPCR. Ratio of upregulation in the ipsilateral side to PNI for each individual animal was calculated and the mean value was compared between siCont and siMafB-treated animals (n = 5 each, P2rx4; * p < .05; t = 2.403, P2rx7; * p < .05; t = 2.72, Student's t test)
